What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 7.81: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
67.54BINR723.78M · vs all stocks (USD)
Trailing P/E
68.85xRevenue (TTM)
17.56BINR188.20M · vs all stocks (USD)
Profit Margin
5.71%Beta
0.5410xvs all stocks
52-Week Change
154.23%vs all stocks
Market Capitalization
67.54BINR723.78M · vs all stocks (USD)
Enterprise Value
21.62BINR231.70M · vs all stocks (USD)
Trailing P/E
68.85xPrice to Sales (TTM)
3.85xPrice to Book (MRQ)
5.66xEnterprise to Revenue
1.23xEnterprise to EBITDA
17.75xGross Margin
44.10%Profit Margin
5.71%Operating Margin
5.78%Return on Assets (TTM)
3.49%Return on Equity (TTM)
8.62%Revenue (TTM)
17.56BINR188.20M · vs all stocks (USD)
Revenue per Share (TTM)
31.66INRUpdated Oct 25, 2026Quarterly Revenue Growth
-6.00%Gross Profit (TTM)
5.95BINR63.76M · vs all stocks (USD)
EBITDA (TTM)
2.06BINR22.09M · vs all stocks (USD)
Net Income (TTM)
1.00BINR10.75M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
18.30%Operating Cash Flow (TTM)
354.88MINR3.80M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-2.74BINR-29.39M · vs all stocks (USD)
Payout Ratio
11.17%Minority Interest (Equity)
6.51MINRFY2026 · Mar 31, 2026Revenue
18.01BINRFY2026 · Mar 31, 2026Cost of Goods Sold
11.58BINRFY2026 · Mar 31, 2026Gross Profit
6.43BINRFY2026 · Mar 31, 2026Operating Income
891.94MINR9.56M · vs all stocks (USD)
Pre-tax Income
1.20BINRFY2026 · Mar 31, 2026Income Tax Expense
242.74MINRFY2026 · Mar 31, 2026Net Income
956.47MINRFY2026 · Mar 31, 2026EBIT
1.36BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
1.47BINRFY2026 · Mar 31, 2026Research & Development
53.61MINRFY2026 · Mar 31, 2026Selling, General & Administrative
1.28BINRFY2026 · Mar 31, 2026Other Operating Expenses
1.51BINRFY2026 · Mar 31, 2026Non-operating Interest Income
16.93MINRFY2026 · Mar 31, 2026Non-operating Interest Expense
160.74MINRFY2026 · Mar 31, 2026EPS (Basic)
1.73INRFY2026 · Mar 31, 2026EPS (Diluted)
1.73INRFY2026 · Mar 31, 2026Basic Shares Outstanding
548.42MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
548.42MSharesFY2026 · Mar 31, 2026Minority Interests (P&L)
-7.70MINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
408.78MINRFY2026 · Mar 31, 2026Free Cash Flow
-435.92MINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
311.90MINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
1.20BINRFY2026 · Mar 31, 2026Other Non-cash Items
164.14MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-1.43BINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
472.99MINRFY2026 · Mar 31, 2026Capital Expenditures
-844.69MINRFY2026 · Mar 31, 2026Net Intangibles (CF)
-750.20MINRFY2026 · Mar 31, 2026Net Acquisitions
306.46MINRFY2026 · Mar 31, 2026Other Investing Activity
-433.16MINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-971.40MINRFY2026 · Mar 31, 2026Long-term Debt Issuance
1.32BINRFY2026 · Mar 31, 2026Long-term Debt Payments
-73.23MINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
-90.85MINRFY2026 · Mar 31, 2026Common Dividends Paid
-108.58MINRFY2026 · Mar 31, 2026Other Financing Charges
149.75MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
1.19BINRFY2026 · Mar 31, 2026Shares Outstanding
547.95MSharesUpdated Oct 25, 2026Float Shares
309.63MSharesUpdated Oct 25, 2026% Held by Insiders
42.69%vs all stocks
% Held by Institutions
1.38%vs all stocks
Total Cash (MRQ)
808.74MINR8.67M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.47INRUpdated Oct 25, 2026Total Debt (MRQ)
1.58BINR16.98M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1324xCurrent Ratio (MRQ)
2.23xBook Value per Share (MRQ)
21.77INRUpdated Oct 25, 2026Total Assets
19.36BINR207.49M · vs all stocks (USD)
Total Current Assets
11.64BINRFY2026 · Mar 31, 2026Total Liabilities
6.89BINRFY2026 · Mar 31, 2026Total Non-current Assets
7.73BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
1.99BINRFY2026 · Mar 31, 2026Total Current Liabilities
4.90BINRFY2026 · Mar 31, 2026Cash
311.90MINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
311.90MINRFY2026 · Mar 31, 2026Other Short-term Investments
228.73MINRFY2026 · Mar 31, 2026Accounts Receivable
3.33BINRFY2026 · Mar 31, 2026Inventory
2.72BINRFY2026 · Mar 31, 2026Accounts Payable
3.17BINRFY2026 · Mar 31, 2026Short-term Debt
699.94MINRFY2026 · Mar 31, 2026Other Current Liabilities
30.35MINRFY2026 · Mar 31, 2026Long-term Debt
1.38BINRFY2026 · Mar 31, 2026Common Stock (Book)
1.10BINRFY2026 · Mar 31, 2026Retained Earnings
4.88BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
12.47BINR133.65M · vs all stocks (USD)
52-Week Low
33.44INRUpdated Oct 25, 202652-Week High
150.70INRUpdated Oct 25, 202652-Week Change
154.23%vs all stocks
Beta
0.5410xvs all stocks
50-Day MA
39.86INRUpdated Oct 25, 2026200-Day MA
51.59INRUpdated Oct 25, 2026Avg 10-Day Volume
672.63KSharesUpdated Oct 25, 2026Avg 30-Day Volume
1.08MSharesUpdated Oct 25, 2026Diluted EPS (TTM)
1.79INRUpdated Oct 25, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 10,747,136.547Operating Cash Flow (USD, TTM): 3,803,248.96
High gross margins eroded by operating costsNotable
Gross Margin: 0.44Profit Margin: 0.06
Financial Health
Altman Z-Score 7.81: safe zoneNotable
Altman Z-Score: 7.81
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shenzhen Lifotronic Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Huakang Century Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing SL Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lionco Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hainan Haiyao Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wave Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hubei Biocause Heilen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Supriya Lifescience Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Chunlizhengda Medical Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Geron Corporation
Tier 1ProductionApproval-Gated PipelineRule